Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 30;15(1):4838.
doi: 10.5826/dpc.1501a4838.

Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy

Federico Pirro  1   2 , Giacomo Caldarola  1   2 , Nicoletta Bernardini  3 , Maria Grazia Celeste  4 , Annunziata Dattola  5 , Eleonora De Luca  1   2 , Marco Galluzzo  6 , Domenico Giordano  7 , Chiara Izzi  4 , Giulia Maretti  8 , Lorenzo Marcelli  6 , Roberto Ravasio  9 , Antonio Giovanni Richetta  5 , Nevena Skroza  3 , Marina Talamonti  6 , Arianna Zangrilli  6 , Luca Bianchi  6 , Giovanni Pellacani  5 , Severino Persechino  7 , Concetta Potenza  3 , Ketty Peris  1   2 , Clara De Simone  1   2
Affiliations

Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy

Federico Pirro et al. Dermatol Pract Concept. .

Abstract

Introduction: Risankizumab and secukinumab are effective treatment options for patients with moderate to severe psoriasis.

Objectives: We sought to estimate the efficacy and the cost per responder of risankizumab and secukinumab by comparing these two drugs in a real-life setting.

Methods: A multicentric retrospective study was conducted in patients from the Lazio region of Italy affected by moderate-to-severe psoriasis who initiated risankizumab or secukinumab between September 2020 to September 2022. Psoriasis Area and Severity Index (PASI) was measured at baseline and after 16, 52, and 78 weeks. Clinical responses were evaluated by PASI90 and PASI100 responses at the same timepoints. The cost per responder at week 16 and 52 was adopted as a cost-effectiveness indicator.

Results: Included were 141 patients, 74 (52.5%) treated with risankizumab and 67 (47.5%) treated with secukinumab. PASI90 responses in risankizumab-treated patients were higher than those observed in patients treated with secukinumab at both weeks 16 and 52 (79.7% versus 64.2% (P = 0.041) and 98.6% versus 83.6% (P = 0.003), respectively). Risankizumab also showed superior PASI100 rates at week 52 (85.5% versus 65.6%, P = 0.009). No statistically significant differences were observed in PASI90 and PASI100 rates between the 2 groups at week 78. The cost per PASI90 and PASI100 responder for risankizumab was lower at both weeks 16 (€5833.66 and €8394.78, compared to €8747.18 and €10746.53 for secukinumab) and 52 (€11798.90 and €13598.73 vs €15347.70 and €19568.31, respectively).

Conclusions: Risankizumab showed superior efficacy than secukinumab and a lower cost per responder.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: None.

Figures

Figure 1
Figure 1
Proportions (%) of patients achieving Psoriasis Area and Severity Index (PASI)90 and PASI100 responses at weeks 16, 52 and 78.
Figure 2
Figure 2
Cost per Psoriasis Area and Severity Index (PASI)90 and PASI100 responder patient at weeks 16 and 52.
See this image and copyright information in PMC

References

    1. Prignano F, Rogai V, Cavallucci E, Bitossi A, Hammen V, Cantini F. Epidemiology of Psoriasis and Psoriatic Arthritis in Italy-a Systematic Review. Curr Rheumatol Rep. 2018;20(7):43. doi: 10.1007/s11926-018-0753-1. - DOI - PubMed
    1. Gianfredi V, Casu G, Bricchi L, Kacerik E, Rongioletti F, Signorelli C. Epidemiology of psoriasis in Italy: burden, cost, comorbidities and patients’ satisfaction. A systematic review. Acta Biomed. 2022;93(6):e2022332. - PMC - PubMed
    1. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM Global Psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020 May 28;369:m1590. - PMC - PubMed
    1. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945–1960. - PubMed
    1. Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S2–S6. - PubMed

LinkOut - more resources